Technical Analysis for INFI - Infinity Pharmaceuticals, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 3.04 | -4.40% | -0.14 |
Earnings due: Mar 1
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Down | Down |
Historical INFI trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 50 DMA | Bearish | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Wide Bands | Range Expansion | -4.40% | |
Oversold Stochastic | Weakness | -4.40% | |
Narrow Range Bar | Range Contraction | -10.85% | |
NR7 | Range Contraction | -10.85% | |
Wide Bands | Range Expansion | -10.85% | |
Oversold Stochastic | Weakness | -10.85% | |
1,2,3 Pullback Bullish | Bullish Swing Setup | -10.59% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time | |
---|---|---|
50 DMA Support | 1 day ago | |
Down 5% | 1 day ago | |
Down 3% | 1 day ago | |
Down 2 % | 1 day ago | |
Down 1% | 1 day ago |
Get this analysis on your stocks daily!
- Earnings date: 03/01/2021
Infinity Pharmaceuticals, Inc. Description
Infinity Pharmaceuticals, Inc., a drug discovery and development company, focuses on discovering, developing, and delivering medicines to patients for diseases with significant unmet need. Its lead product candidates include IPI-145 and IPI-443, inhibitors of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K); Retaspimycin HCl, a heat shock protein 90 inhibitor; and IPI-940, an inhibitor of fatty acid amide hydrolase. The company is pursuing a dual development path for IPI-145 in both hematologic malignancies and inflammation. IPI-145 is in an ongoing Phase I dose-escalation trial in patients with advanced hematologic malignancies and in a Phase IIa study in patients with mild, allergic asthma. In addition, the company plans to initiate a Phase II signal-finding study in patients with rheumatoid arthritis. IPI-443 is undergoing preclinical studies to enable Phase I development. Retaspimycin HCl is in a Phase II trial in combination with docetaxel to treat patients with non-small cell lung cancer (NSCLC) and in an exploratory Phase Ib/II trial in combination with everolimus in NSCLC patients with a KRAS mutation. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Diseases Acid Drug Discovery Inflammation Chemical Substances Small Cell Lung Cancer Non Small Cell Lung Cancer Rheumatoid Arthritis Asthma Mild Hematologic Malignancies Fatty Acid Nsclc Phosphoinositide 3 Kinase Inhibitor Docetaxel Kras Pyrimidines Allergic Asthma Purines
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 5.98 |
52 Week Low | 0.6 |
Average Volume | 3,936,470 |
200-Day Moving Average | 1.67 |
50-Day Moving Average | 3.13 |
20-Day Moving Average | 3.81 |
10-Day Moving Average | 3.63 |
Average True Range | 0.48 |
ADX | 35.4 |
+DI | 27.08 |
-DI | 24.16 |
Chandelier Exit (Long, 3 ATRs ) | 4.54 |
Chandelier Exit (Short, 3 ATRs ) | 4.37 |
Upper Bollinger Band | 4.79 |
Lower Bollinger Band | 2.83 |
Percent B (%b) | 0.11 |
BandWidth | 51.46 |
MACD Line | 0.01 |
MACD Signal Line | 0.18 |
MACD Histogram | -0.169 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 3.54 | ||||
Resistance 3 (R3) | 3.56 | 3.41 | 3.46 | ||
Resistance 2 (R2) | 3.41 | 3.28 | 3.40 | 3.43 | |
Resistance 1 (R1) | 3.22 | 3.20 | 3.15 | 3.21 | 3.40 |
Pivot Point | 3.08 | 3.08 | 3.04 | 3.07 | 3.08 |
Support 1 (S1) | 2.89 | 2.95 | 2.82 | 2.87 | 2.68 |
Support 2 (S2) | 2.74 | 2.87 | 2.73 | 2.65 | |
Support 3 (S3) | 2.56 | 2.74 | 2.62 | ||
Support 4 (S4) | 2.54 |